Lee, Chan Sae; Ha, Doo Chul

doi:1966.0.24.183

Tuberc Respir Dis > Issue 24; 1966 > Article

Tuberculosis and Respiratory Diseases 1966;24:183-186.
DOI: https://doi.org/10.4046/trd.1966.24.1.183 Published online December 1, 1966.

"DATC" IN THE TREATMENT OF PULMONARY TUBERCULOSIS

Chan Sae Lee, Doo Chul Ha

Department of Internal Medicine, Catholic Medical College, Seoul, Korea

Abstract

1)DATC(Isoxyl) (4-4' Diisoamyloxythiocarvanilide) has been tried on 50 cases of chronic resistant pulmonary tuberculosis patients to check the clinical significance. This was given in dose of 1.0~1.5 gm bid together with INH 200 mg bid for 5 months or more. 2) Bacteriological negative conversion of sputum occurred in about 27% and the marked X-ray improvement attained in about 10% and three was no remarkable side effect noted. 3) This was far superior in it's effectiveness and much safer to compare with author's own previous experience of DETC(Esoxyl, Tiberon)(4-4' Diehoxylthiocatbanilide). 4) The author inclined to assume that DATC could be used as one of secondary drugs in the treatment of chronic pulmonary tuberculosis same as 1314th or pyrazinamide. However the author could not be clarified on the possibility of replacing PAS with DATC in primary chemotherapy cases for former's frequent side effects.